Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | Q56_V60del |
Impact List | deletion |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 Q56_V60del results in the deletion of five amino acids in the protein kinase domain of the Map2k1 protein from amino acids 56 to 60 (UniProt.org). Q56_V60del confers a gain of function to the Map2k1 protein as indicated by transformation capabilities and increased phosphorylation of Erk and S6k in culture (PMID: 26324360). |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 Q56_V60del |
Transcript | NM_002755.4 |
gDNA | chr15:g.66435112_66435126del15 |
cDNA | c.166_180del15 |
Protein | p.Q56_V60delQKQKV |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011521783.3 | chr15:g.66435178_66435192del15 | c.166_180del15 | p.N56_V60delNGGVV | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66435112_66435126del15 | c.166_180del15 | p.Q56_V60delQKQKV | RefSeq | GRCh38/hg38 |
XM_011521783 | chr15:g.66435178_66435192del15 | c.166_180del15 | p.N56_V60delNGGVV | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66435112_66435126del15 | c.166_180del15 | p.Q56_V60delQKQKV | RefSeq | GRCh38/hg38 |
XM_017022413 | chr15:g.66484990_66485004del15 | c.166_180del15 | p.P56_Q60delPERLQ | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66435112_66435126del15 | c.166_180del15 | p.Q56_V60delQKQKV | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66435178_66435192del15 | c.166_180del15 | p.N56_V60delNGGVV | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66435112_66435126del15 | c.166_180del15 | p.Q56_V60delQKQKV | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66435178_66435192del15 | c.166_180del15 | p.N56_V60delNGGVV | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66435178_66435192del15 | c.166_180del15 | p.N56_V60delNGGVV | RefSeq | GRCh38/hg38 |
XM_017022413.1 | chr15:g.66484990_66485004del15 | c.166_180del15 | p.P56_Q60delPERLQ | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66435112_66435126del15 | c.166_180del15 | p.Q56_V60delQKQKV | RefSeq | GRCh38/hg38 |
XM_011521783.4 | chr15:g.66435178_66435192del15 | c.166_180del15 | p.N56_V60delNGGVV | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66435112_66435126del15 | c.166_180del15 | p.Q56_V60delQKQKV | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 Q56_V60del | ovarian serous carcinoma | predicted - sensitive | Selumetinib | Case Reports/Case Series | Actionable | In a Phase II trial, Koselugo (selumetinib) treatment resulted in a complete response that lasted over 5 years with continuous treatment in a patient with serous ovarian cancer harboring MAP2K1 Q56_V60del (PMID: 26324360). | 26324360 |